[CROATIAN GUIDELINES FOR THE PHARMACOTHERAPY OF TYPE 2 DIABETES].

Autor:	Rahelić D, Altabas V, Bakula M, Balić S, Balint I, Marković BB, Bicanić N, Bjelinski I, Bozikov V, Varzić SC, Car N, Berković MC, Orlić ZC, Deskin M, Sunić ED, Tomić NG, Goldoni V, Gradiser M, Mahecić DH, Balen MJ, Erzen DJ, Majanović SK, Kokić' S, Krnic M, Kruljac I, Liberati-Cizmek AM, Martina L, Metelko Z, Mirosević G, Vrbica SM, Renar IP, Petric D, Prasek M, Prpić-Kizevać I, Radman M, Soldo D, Sarić T, Tesanović S, Kurir TT, Wensveen TT, Botica M, Vrkljan M, Rotkvic VZ, Zorić C, Krznarić Z
Jazyk:	chorvatština
Zdroj:	Lijecnicki vjesnik [Lijec Vjesn] 2016 Jan-Feb; Vol. 138 (1-2), pp. 1-21.
Abstrakt:	Introduction: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of diabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the pharmacotherapy of type 2 diabetes in the Republic of Croatia. Participants: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. Evidence: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. Conclusions: An individual patient approach based on physiological principles in blood glucose control is essential for diabetes' patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglyce- mia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu